At the Thirteenth International Kidney Cancer Symposium, Dr Sumanta Pal (City of Hope Comprehensive Cancer Center, CA) discusses papillary renal cell carcinoma (pRCC) and a phase 2 clinical trial on the MET inhibitor, volitinib, in patients with pRCC.
Although pRCC comprises 1015% of renal cell carcinoma, current understanding and management of this disease is relatively limited. Inappropriate MET activation in cancer cells may be important in pRCC progression. Volitinib is a novel, selective and potent MET inhibitor. Preliminary clinical trials on volitinib in pRCC are promising. This new phase 2 trial aims to further evaluate the efficacy and safety of volitinib in patients.
Advertisement